Serum response factor (SRF) is a widely expressed transcription factor involved in immediate-early and tissue-specific gene expression, cell proliferation and differentiation. We defined a new role of SRF as a nuclear repressor of the tumor growth factor b1 (TGF-b1) growth-inhibitory signal during cell proliferation. We show that SRF significantly inhibits the TGF-b1/Smaddependent transcription by associating with Smad3. SRF causes resistance to the TGF-b1 cytostatic response by directly repressing the Smad transcriptional activity and Smad binding to DNA. Furthermore, we demonstrated that overexpression of SRF markedly decreases the level of Smad3 complex binding to the promoters of Smad3 target genes, p15
Introduction
Transforming growth factor b (TGF-b) is an important regulator of many diverse developmental and homeostatic processes, and the disruption of their activity has been implicated in a variety of human diseases including cancer (de Caestecker et al., 2000; Massague and Chen, 2000) . TGF-b signals are transduced by transmembrane serine-threonine kinase receptors and intracellular effector Smads (Derynck et al., 1998; Shi and Massague´, 2003) . Upon the binding of TGF-b to its receptors, Smad2 and/or Smad3 are phosphorylated at their C termini by the type I receptor. The phosphorylated Smad2/3 are engaged in a complex with Smad4 and then translocated into the nucleus. In the nucleus, the heteromeric Smad complex regulates transcription through its ability to interact with DNA-binding and non-DNA-binding transcription cofactors (Wrana and Attisano, 2000) . This family of intracellular mediators, the Smads, has provided new paradigms for understanding mechanisms of TGF-b signaling.
Serum response factor (SRF) is a widely expressed transcription factor involved in orchestrating disparate programs of gene expression linked to muscle differentiation and cellular growth (Treisman, 1992; Miano, 2003) . Serum response factor (SRF) is a ubiquitously expressed protein belonging to the MADS box family of nuclear transcription factors. The MADS-box is named after the first four proteins in which this domain was identified minichromosome maintenance 1 (MCM1), AGAMOUS (AG), DEFICIENS and serum response factor (SRF). SRF has been implicated in cellular processes such as immediate-early and tissue-specific gene expression, cell proliferation, differentiation and apoptosis (Treisman, 1992; Schratt et al., 2001; Chai and Tarnawski, 2002; Miano, 2003) . SRF is also activated in response to various stimuli, including serum, growth factors and intracellular calcium-regulating agents (Treisman, 1994) . SRF is regulated by changes in actin dynamics to promote transcription of vinculin and actin, both necessary for the cytoskeletal changes essential to motility and invasion (Sotiropoulos et al., 1999) . However, little is known of its implication in tumorigenesis. A recent report has shown that SRF plays an important role in tumor progression, specifically at the transition to an invasive metastatic stage of carcinogenesis (Psichari et al., 2002) .
Serum can interfere with the biological activity of TGF-b. Inhibition of cell proliferation of CCL64 mink lung epithelial cells by TGF-b required a higher concentration of TGF-b in the presence of serum as compared to serum-free condition (Garrigue-Antar et al., 1995) . Although factors released by cells, serum cytokines and serum proteins such as a2-macroglobulin (Danielpour and Sporn, 1990 ) may modify TGF-bmediated growth inhibition, we cannot exclude the possibility that other factors such as SRF, which is known to be induced by the serum, could also modulate TGF-b activity. Therefore, in this study, we examined whether TGF-b signaling is modulated by seruminduced SRF. Here, we describe a novel mechanism in which SRF inhibits TGF-b signaling through the interaction with receptor-activated Smads, Smad2 and Smad3. We show that SRF does not block TGF-binduced Smad2/3 phosphorylation, but that SRF inhibits the DNA-binding activity of the Smad3/Smad4 complex. Thus, SRF is a nuclear repressor of TGF-b signaling; its function is to suppress TGF-b growthinhibitory activity by blocking the transcriptional activity of the Smad complex.
Results

Serum represses TGF-b1/Smad3-dependent transcription
We first examined whether serum can interfere with the biological activity of TGF-b. HepG2 cells were transfected with either the Smad/TGF-b-responsive SBE4-luc reporter construct, which contains four tandem repeats of SBE (Smad-binding element) (Zawel et al., 1998) , or the 3TP-lux reporter construct. After transfection, cells were subjected to serum-starved conditions for 24 h and then incubated with 20% serum in the presence or absence of TGF-b1. The addition of serum suppressed TGF-b-induced SBE reporter activity, but only moderately inhibited TGF-b1 induced 3TP-lux reporter activity (Figure 1a and b). We have also observed the repressive effect of serum on the TGF-b induced activity of these reporters in Mv1Lu mink lung epithelial cells (see Supplementary Figure 1) . As a positive control of the serum effect, we examined the effect of serum on the serum response element (SRE-Luc) reporter activity ( Figure 1c) . To confirm the activation of SRF by the addition of 20% serum after 24 h serum starvation, we examined the phosphorylation of SRF at Ser-103. SRF contains a number of phosphorylation sites , and it is a target of several kinase pathways (Manak and Prywes, 1991; Janknecht et al., 1992; Liu et al., 1993; Rivera et al., 1993; Iyer et al., 2003 Iyer et al., , 2006 . The physiological importance of these modifications remains unsettled. To confirm the status of SRF phosphorylation by the addition of 20% serum, we examined the phosphorylation of SRF at Ser-103. As expected, we observed After transfection, cells were subjected to the serum starvation for 24 h and then serum was added (20% FBS). One hour after serum addition, cells were treated with TGF-b1 for 8 h and then luciferase activity was measured. SRE-Luc reporter was used as a control reporter for SRF (c). HepG2 cells were subjected to the serum starvation for 24 h and then serum was added (20% fetal bovine serum). Two hours after serum addition, cells were treated with TGF-b1 for 30 min. Smad3 phosphorylation was examined by anti-pSmad3 immunoblotting and phosphorylation of SRF at Ser-103 was examined by immunoblotting using anti-SRF Ser-103 antibody (Cell Signaling Technology Inc., Beverly, MA, USA).
serum-induced phosphorylation of SRF at Ser-103 by the addition of 20% serum (Figure 1d ). Interestingly, serum induced Smad3 phosphorylation slightly. However, serum did not inhibit the Smad3 phosphorylation induced by TGF-b1.
SRF represses TGF-b1/Smad3-dependent transcription To determine whether suppression of TGF-b1/Smad3-dependent transcription by serum mediates through the SRF, HepG2 cells were co-transfected with an SRF expression construct and either the Smad/TGF-bresponsive SBE4-luc reporter construct or the 3TP-lux reporter construct. Introduction of SRF suppressed TGF-b-induced SBE reporter activity, but only moderately inhibited TGF-b-induced 3TP-lux reporter activity (Figure 2a and b) . We have also observed the repressive effect of SRF on the TGF-b-induced activity of these reporters in other cell types, including Mv1Lu mink lung epithelial cells and HaCaT human keratinocytes (data not shown). SRF suppressed the TGF-b-induced transcriptional activities of the SBE4-luc and the 3TP-lux reporter gene constructs in a dose-dependent manner (Figure 2c and d). SRF itself increased the basal activity of 3TP-lux. This effect may be mediated through the three consecutive activator protein-1 (AP-1)-binding elements present in the 3TP-Lux reporter (Wrana et al., 1992) because c-fos, a component of the AP-1 complex, is transcriptionally activated by SRF (Treisman, 1992; Paradis et al., 1996.) . As a positive control of the SRF effect, we examined the effect of SRF on the serum response element (SRE-Luc) reporter activity ( Figure 2e ). To determine whether SRF can directly suppress the Smad transcriptional activity, we used a heterologous reporter assay in which the GAL4 DNA-binding domain was fused to various Smad proteins. GAL4-Smad3 or Gal4-Smad4 expression constructs were co-transfected with a luciferase reporter construct (G5E1b-lux), which contains five GAL4-binding sites upstream of the AdE1b TATA box. As shown in Figure 2f , TGF-b treatment slightly induced transcription by the minimal GAL4-DNA-binding domain, but SRF did not have any effect on its transcription. However, SRF strongly suppressed the TGF-b-induced transcriptional activity of GAL4-Smad3 fusion protein, but not GAL4-Smad4 fusion protein (Figure 2f ).
SRF interacts with Smad3
To examine the possibility that SRF interacts directly with Smad proteins in vivo, 293T cells were transfected Luciferase activity was measured 24 h after TGF-b1 stimulation. Dose responsiveness of SRF on SBE4-luc (c) and 3TP-lux (d) was also examined in HepG2 cells. SRE-Luc reporter was used as a control reporter for SRF (e). HepG2 cells were cotransfected with Gal4-Smad3 or Gal4-Smad4 and reporter plasmid G5E1b-lux, and a plasmid for SRF (f). Transcriptional activity from the reporter plasmid was measured. Assays were performed in the presence or absence of TGF-b1.
with Flag-tagged Smad3 or Myc-tagged Smad4 and HA-tagged SRF (pCGN-SRF) with or without the constitutively active TGF-b type I receptor (ALK5TD). SRF interacts with Smad3 in an activated ALK5-independent manner (Figure 3a) . SRF also interacts with Smad2 (manuscript submitted). The direct interaction between Smad3 and SRF was also studied by glutathione-S-transferase (GST) pull-down assays in vitro using 35 S-labeled SRF proteins. GST-Smad3 interacted with 35 S-labeled SRF (Figure 3b) . To check the cellular localization of endogenous Smads and SRF, confocal microscopy was performed in Mv1Lu cells. Smad3 was found in both cytoplasmic and nuclear compartments, but predominantly in the nucleus. Upon TGF-b stimulation, Smad3 almost completely translocated into the nucleus (Figure 3c ). SRF localizes in the nucleus with or without TGF-b1 stimulation.
We next determined whether endogenous SRF interacts with Smad3. To this end, we performed immunoprecipitation experiments using Mv1Lu cellular extracts. Endogenous SRF was able to interact with Smad3, whereas endogenous interaction between Smad4 and SRF was very weak to undetectable (Figure 3d ). Endogenous SRF associated with Smad3 without ligand stimulation. Therefore, our data strongly suggest that the SRF protein directly interacts with Smad3 under physiological conditions.
Mapping of interacting domains of SRF and Smad3
We next attempted to determine which region of SRF is responsible for the interaction with Smad3 and the suppression of TGF-b-induced transcriptional activity. We generated various deletion mutants lacking the DNA-binding domain or the trans-activation domain of SRF. We first examined the effect of SRF mutants on TGF-b-induced transcriptional activity. The deletion mutants containing the MADS box domain retained the suppressive property (Figure 4a , middle panel). The suppressive activity of these deletion mutants correlated well with their ability to interact with Smad3 ( Figure 4a , bottom panel). The GST-tagged SRF mutant (224-508), which lacks the MADS box domain, did not interact with Smad3, whereas the MADS box containing mutant (114-245) was able to interact with Smad3. SRF mutant (114-245) exclusively localized in the nucleus, whereas SRF mutant (224-508) primarily localized in the nucleus, but was also detected in the cytoplasm (data not shown). These results suggest that the MADS box of SRF is responsible for the interaction with Smad3 and may mediate its suppressive activity on TGF-b-induced transcriptional activity.
We also mapped the domain of Smad3 that is involved in the interaction with SRF by immunoprecipitation assays using various Flag-tagged Smad3 expression constructs along with a GST-tagged wild-type SRF construct. The C-terminal deletion mutants lacking the MH2 or Linker þ MH2 domains of Smad3 were unable to bind to SRF, whereas the N-terminal mutants, in which MH1 or MH1 þ Linker are deleted, interacted with SRF ( Figure 4b ). The middle linker region is unlikely to interact with SRF because the MH1 þ Linker did not interact with SRF.
SRF overexpression blocks TGF-b-induced growth inhibition
To further investigate the role of SRF in TGF-b signaling, we generated Mv1Lu cells stably expressing SRF. We first examined the expression of smooth muscle a-actin (SM a-actin), a target gene of SRF, that contains consensus CArG motifs (Mack and Owens, 1999) . Overexpression of SRF markedly increased SM a-actin expression (Figure 5a ). Consistent with the results of the transient transfection experiments shown in Figure 1 , the activities of the TGF-b reporters, 3TP-lux and SBE4-luc, were markedly decreased in Mv1Lu cells stably expressing SRF (Figure 5b and c) . As a control, we examined the promoter activity of SM a-actin gene. Overexpression of SRF markedly increased SM a-actin expression, contrary to it not being induced in the cells expressing the mutant SRF, SRF-pml (Kim et al, 1994) , which carries three point mutations in the basic region of SRF that abolishes its DNA-binding activity ( Figure 5d ). We also examined whether SRF suppresses the transcriptional activity of other TGF-b1-induced endogenous genes. For this purpose, we examined the expression of plasminogen activator inhibitor 1 (PAI-1) and the a2 type I collagen gene (COL1A2) by Northern blot analysis. PAI-1 and COL1A2 mRNA levels were upregulated upon the addition of TGF-b1 in vector control Mv1Lu cells, but markedly decreased in SRF-expressing Mv1Lu cells (Figure 5e ). The promoter activity of PAI-1 gene was significantly decreased in SRF expressing Mv1Lu cells (Figure 5f ). To examine the effects of SRF on TGF-binduced inhibition of cell proliferation, we performed , which is a TGF-bresponsive cyclin-dependent kinase (CDK) inhibitor, and was not induced even with TGF-b treatment. Interestingly, the endogenous p21
Cip1 level was markedly decreased in Mv1Lu cells expressing SRF (Figure 6a ). TGF-b is known to induce both p15
INKb and p21
Cip1 expression in SNU620 cells (Kang et al., 1999) . Therefore, we examined whether SRF suppresses both endogenous p21 Cip1 and p15 INKb protein levels induced by TGF-b1 in SNU620 human gastric cancer cells expressing SRF. The level of endogenous SRF protein was low to undetectable in SNU620, which are sensitive to TGF-b growth-inhibitory activity (data not shown). We found that SRF expression markedly suppressed TGF-b-induced p21
Cip1 and p15 INKb protein expression levels (Figure 6e ). SRF also inhibited transcription from the p21
Cip1 gene promoter in a reporter assay (Figure 6d) . Interestingly, the expression of p27
Kip1 was unaffected by the expression of SRF. Collectively, these data indicate that SRF directly suppresses TGF-b signaling and that overexpression of SRF may lead to the inactivation of TGF-b signaling.
The growth-suppressive function of the retinoblastoma gene product, RB, has been ascribed to the underphosphorylated RB form that prevails during the G1 phase of the cell cycle. The addition of TGF-b to Mv1Lu cells prevents the phosphorylation of RB scheduled for this cell cycle stage and arrests cells in late G1 (Laiho et al., 1990) . The suppressive effect of TGF-b on Rb phosphorylation was markedly attenuated in Mv1Lu cells expressing SRF compared to the control cells (Figure 6a ). The cytostatic effect of TGF-b in certain cell types is dependent on the ability of TGF-b to repress the transcriptional initiation of the protooncogene c-myc (Alexandrow et al., 1995) . The basal expression of c-Myc was markedly enhanced in Mv1Lu cells expressing SRF, and TGF-b was still able to repress c-Myc expression even though the degree of c-Myc downregulation was not as much compared to those in the control cells (Figure 6a ).
We next examined the effect of SRF on the expression of cyclin-dependent kinases regulated by TGF-b in Mv1Lu stable cells. The antimitogenic response to TGF-b is generally mediated by gene responses that directly compromise the activity of G 1 -phase CDKs (cdk4, cdk6, and cdk2) and by the downregulation of c-myc (Ewen et al., 1993; Warner et al., 1999) . The cdk-inhibitory responses of TGF-b can vary depending on the cell type. TGF-b1 induced the suppression of Cdk1, Cdk4, Cdk6 and also cyclin D1 synthesis in the control Mv1Lu cells. In agreement with previous report (Abraham et al., 1992) , we see a decline in the steady-state level of Cdk1 level after TGF-b1 treatment. SRF expression prevented TGF-b-mediated suppression of Cdk1, Cdk4, Cdk6 and cyclin D1 expression (Figure 6f) .
We also performed loss of function studies using SRF-specific small interfering (siRNA) to evaluate the specific effect of SRF on TGF-b signaling. We were able to reduce endogenous SRF expression to 70-90% of its original level through RNA-mediated interference using 50-100 nM of SRF-specific siRNA (Figure 7a ). Transfection with SRF-specific siRNA increased TGF-b-induced SBE4-luc activity, demonstrating that endogenous SRF acts as a negative modulator in TGF-b signaling. We also examined the effect of SRF-specific siRNA duplexes on TGF-b1-induced p21
Cip1 expression. Treatment with SRF-specific siRNA duplexes increased the steady-state levels of p21
Cip1
, and TGF-b1 treatment further induced p21
Cip1 expression levels (Figure 7b ).
SRF inhibits endogenous Smad complex formation and Smad binding to DNA
The transcriptional activities of both Smad2 and Smad3 are dependent on their phosphorylation by activated TbRI. Therefore, we examined whether SRF regulates TGF-b-stimulated Smad3 phosphorylation. SRF expression had little effect on TGF-b-stimulated phosphorylation of endogenous Smad3 in Mv1Lu cells expressing SRF compared to the control cells (Figure 8a ), suggesting that effects of SRF are positioned downstream of Smad3 phosphorylation.
Since our results suggest that the actions of SRF are positioned downstream of Smad3 phosphorylation, we examined the possibility that SRF may block the ability of the Smad3/4 complex to bind DNA. The fact that SRF mainly localizes in the nucleus also supports this hypothesis. Using Flag-tagged Smad3 and HA-tagged SRF constructs, we performed the CAGA-binding assay after transient transfection into HepG2 cells. The amount of Smad3 bound to the CAGA sequence was markedly increased by TGF-b treatment (Figure 8b) . However, the introduction of SRF markedly reduced the amount of the Smad3 bound to CAGA dosedependently (Figure 8b ). To confirm the nuclear interaction of Smad3 with SRF, we performed cell fractionation experiments using control and SRFexpressing Mv1Lu cells. Examination of the fractions for Smad3, Smad4 and SRF proteins showed that SRF is primarily a nuclear protein, whereas Smad3 and Smad4 were detected in both cytosolic fractions and nuclear fractions in control cells. However, Smad4 is predominantly localized to the nuclear compartment. Both Smad3 and Smad4 proteins were not detected in cytosolic fractions in SRF-expressing cells. TGF-b treatment markedly increased levels of nuclear Smad3 in both control and SRF-expressing Mv1Lu cells. To demonstrate that SRF disrupts Smad3-Smad4 complex formation in the nucleus, we performed INK4b reporter and SRF. Reporter assays were performed as described previously. (e) We generated the SRF-overexpressing cells in SNU620 human gastric cancer cells. SRF-expressing SNU620 cells and control cells were incubated in the presence or absence of TGF-b1. Protein levels of CDK inhibitors, p15
INK4b and p21 Cip1 , on whole-cell lysates were examined by Western blot analysis. (f) Mv1Lu-SRF and control cells were incubated in the presence or absence of TGF-b1 for 18 h. CDK protein level on whole-cell lysates was examined by Western blot analysis.
immunoprecipitation experiments using nuclear fractions. As shown in Figure 8c , the level of Smad3 bound to Smad4 was markedly decreased in nuclear fractions in SRF-expressing Mv1Lu cells compared to vector control cells. Collectively, these data indicate that SRF inhibits TGF-b signaling through the blocking of Smad complex formation and thereby inhibiting its DNAbinding activity.
To see whether SRF blocks the ability of the Smad3/4 complex to bind to DNA, we performed a chromatin crosslinking experiment. Control SNU620 cells and SRF-expressing SNU620 cells were cultured in the presence or absence of TGF-b1. These cells were then treated with formaldehyde and crosslinked chromatin from equivalent numbers of these cells, and were immunoprecipitated using antibodies against Smad3. After immunoprecipitation, enrichment of the endogenous p21 Cip1 Feng et al., 2002) . As shown in Figure 9 , Smad complex binding induced by TGF-b1 treatment was markedly decreased in SRF expressing SNU620 cells.
Discussion
In this study, we have identified a novel mechanism to suppress TGF-b-induced cell cycle arrest by SRF. During cell cycle progression, SRF is known to induce genes involved in cell proliferation. SRF binds to an SRE, which is associated with a variety of genes including immediate early genes, such as c-fos, junB, egr-1 and egr-2, and muscle genes, such as SM a-actin (Treisman, 1995; Miano, 2003) . By regulating the expression of these genes, SRF controls cell growth and differentiation, as well as muscle development and function. Here, we described a new role for SRF, which places it as a suppressor of the TGF-b transcriptional activity that directly represses Smad transcriptional activity, thereby leading to the inhibition of expression of TGF-b-responsive genes such as PAI-1, p15 INK4b and p21
Cip1
.
In this study, we demonstrated that SRF regulates TGF-b signaling through its interaction with Smad3. The interaction between Smad3 and SRF does not depend on TGF-b signaling. This may be owing to the level of nuclear Smads as SRF is exclusively localized in the nucleus. Our confocal microscopy experiment demonstrated that Smad3 was localized mostly in the nucleus even without TGF-b1 in Mv1Lu cells. The unchecked activation of an autocrine TGF-b loop may result in the nuclear localization of Smad3. Since Smad3 also interacts with in vitro translated SRF proteins, it is likely that nuclear localization of Smad3 may be important for its interaction with SRF, which is exclusively localized in the nucleus, rather than the phosphorylation of SRF.
TGF-b is the most potent inhibitor of cell cycle progression of epithelial cells. This effect is mediated by several events that are activated downstream of the TGF-b receptor. This includes the transcriptional repression of the proto-oncogene c-myc (Alexandrow et al., 1995), downmodulation of the expression and activities of G1 and G2 CDK and cyclins (Ewen et al., 1993; Geng and Weinberg, 1993; Iavarone and Massague, 1997) , and activation of the genes encoding p15
INK4b (Hannon and Beach, 1994) , p21
Cip1 (Datto et al., 1995; Claassen and Hann, 2000) and p27
Kip1 (Polyak et al., 1994; Depoortere et al., 2000) INK4b by TGF-b is mediated by a TGF-b-induced complex of Smad2, Smad3, Smad4 and Sp1 (Feng et al., 2000) . The intracellular effectors of TGF-b, Smad3 and Smad4, also functionally cooperate with Sp1 to activate the human p21
Cip1 promoter (Pardali et al., 2000) . Therefore, it is likely that SRF directly abrogates the TGF-b-induced p21
Cip1 and p15 INK4b transcription by inhibiting the Smad-dependent transcriptional activation. The fact that the overexpression of SRF markedly decreases the level of the Smad complex binding to DNA further supports the notion that SRF abrogates the TGF-b-induced p21
Cip1 and p15 INK4b transcription through its interaction with Smads. TGF-b treatment slightly induced p27
Kip1 expression in Mv1Lu cells, but SRF had no effect on the TGF-b-induced p27 Cells were treated with 5 ng/ml TGF-b1 for 2 h. After pre-clearing with streptavidin-agarose for 1 h, cell lysates were incubated with 30 pmol of biotinylated doublestranded 3 Â CAGA oligonucleotides and 12 mg of poly(dI-dC) for 1 h. Proteins were precipitated with streptavidin-agarose for 30 min. After washing, DNA-bound protein was subjected to SDS-PAGE, followed by Western blotting using antibodies. (c) Comparison of subcellular localization of Smad3, Smad4 and SRF. Cytosolic and nuclear lysates prepared from Mv1Lu cells were analysed by SDS-PAGE and immunoblotting using antibodies specific for Smad3, Smad4, SRF and a-tubulin. Effect of SRF on Smad3 complex formation with Smad4 using nuclear lysates was examined. , but TGF-b had no effect on the expression of p21
. However, SRF expression completely eliminated the basal expression of p21
Cip1 in Mv1Lu cells. Since SRF suppressed TGF-b1-induced p21
Cip1 expression in SNU620 cells, these observations suggest that SRF targets the TGF-binduced p15
INK4b and p21 Cip1 transcription, but not p27 Kip1 transcription. Cell cycle progression is delicately controlled by the activity of different CDKs and their regulatory subunits known as cyclins (Lee and Yang, 2003) . CDK2, CDK4, CDK6 and their associated cyclins control the G1 to S phase transition. Progression through the G1 phase is regulated by signal-transduction cascades activated by serum and by polypeptide growth factors. In serumstarved cells, the addition of serum has been shown to induce expression of cyclin D and the assembly of cyclin D with its partner CDK4. Serum-induced SRF and various polypeptide growth factors are important regulators of numerous genes associated with cell growth and differentiation. TGF-b treatment leads to a decrease in the level of Cdks including Cdk4 in Mv1Lu cells (Ewen et al., 1993) . Our results show that SRF overexpression reversed the TGF-b-mediated decrease in the level of Cdk1, 4 and 6, and also cyclin D1. Taken together, our present study has provided direct evidence that SRF expression leads to TGF-b resistance through the inhibition of TGF-b-mediated suppression in the expression of CDKs.
SRF is a member of the MADS box superfamily of transcription factors. The MADS box domain of SRF has been demonstrated to convey gene regulatory activity through associations with other factors, as well as being the DNA-binding domain of the molecule. SRF DNA-binding and dimerization domain are located in the region between amino acids 133 and 222 (Norman et al., 1988) . The Smad3-binding domain in SRF is also located in the DNA-binding domain of SRF and this DNA-binding domain is sufficient in suppressing TGF-b responsiveness. Taken together, our study suggests that SRF can function as both a transcription factor to bind to its target element, SRE, and a transcriptional repressor to bind to the Smad complex to block Smad transcription activity at CAGA sites.
A recent report shows that Smad3 is a transcriptional activator for the SM22 promoter and that Smad3 can bind both directly to SBE sites in the SM22 promoter and associate with CArG box-bound SRF complexes in response to TGF-b1 (Qiu et al., 2003) . SM22 promoter contains two CArG boxes and Smad binding element, suggesting that SRF may bind to CArG boxes preferentially and activate its promoter activity. However, our current results suggest that in the case of genes that have Smad binding element, but no SRF-binding site, SRF may suppress Smad3 transcriptional activity. Therefore, the diversity and specificity of SRF functions may be determined by the collective interactions of its associated transcription factors/cofactors and its DNA-binding sites in the targeted promoters. SRF can function either as a transcriptional activator or repressor, depending on the promoter context.
Increasing lines of evidence suggest that SRF may be involved in the process of transformation in cells of different origins. Recent studies demonstrated that SRF was overabundant and highly active in epithelial tumor cells that had undergone mesenchymal transition (Geng and Weinberg, 1993) . The elevated SRF DNA-binding activity correlated with the increased expression of SRF itself, and with actin and vinculin, which are both SRFdependent genes. Therefore, it will be interesting to see whether elevated SRF expression induces transformation of cells by suppressing the tumor suppressor activity of TGF-b.
Materials and methods
Plasmids and cell lines
Mammalian expression plasmids for Myc-tagged Smad4 and Flag-tagged Smad3 proteins were described previously (Lee et al., 2002) . pCGN-HA-SRF, pCGN-HA-SRF-pm1 and SRE-luciferase reporter constructs were kindly provided by Dr Jae-Hong Kim (Johansen and Prywes, 1993; Kim et al., 1994) . The expression plasmids for GST-tagged SRF and deletion mutants were obtained by PCR using oligonucleotides and cloned into the BamHI and SpeI sites of eucaryotic expression vector pEBG. SRF versions tagged with Flag were generated in the pEF-Flag vector. The p21
Cip1
-and p15
INK4b
-luciferase reporter constructs were kindly provided by X-F Wang (Durham, NC, USA). Mv1Lu, SNU620, HepG2 and HeLa cells were grown as described previously . Mv1Lu-SRF cells that stably express SRF were generated by transfection with the pCI-neo and pCGN-HA-SRF expression plasmids, and SNU620 cells expressing SRF were generated using the LPCX retroviral vector. A day after transfection, cells were split and selected for neomycin resistance. Neomycin-resistant colonies were pooled after 2 weeks of selection, expanded and analysed.
Transcription and reporter assays Transfections, TGF-b treatment, and reporter assays were carried out as described . Briefly, HepG2 cells were transiently transfected with SBE4-luc (Zawel et al., 1998) , 3TP-Lux (Carcamo et al., 1995) and the internal control pCMV-b-gal in six-well plates using Lipofectin (Invitrogen Corp., Rockville, MD, USA) according to the manufacturer's instructions. After a 24 h transfection, cells were treated with 5 ng/ml TGF-b1 for 24 h in media. Luciferase activity was quantified using the Enhanced Luciferase Assay Kit (BD Biosciences-PharMingen, San Diego, CA, USA). Values were normalized with the b-galactosidase activity. All assays were performed in triplicate and represented as the mean (7s.e.) of three independent transfections.
Immunoblotting and Immunoprecipitation
Mv1Lu or 293 T cells were used for the detection of proteinprotein interaction in vivo. The 293 cells were transiently transfected with the indicated plasmids. After a 24 h transfection, cells were switched to 0.2% serum overnight, and induced with 5 ng/ml TGF-b1 for 2 h. Cells were lysed in a buffer containing 25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.5, 150 mM NaCl, 1% Triton X-100, 10% glycerol, 5 mM ethylenediaminetetraacetic acid (EDTA) and protease inhibitor cocktail (Roche, Indianapolis, IN, USA). Extracts were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) followed by electrotransfer to polyvinylidine fluoride membranes and probed with polyclonal or monoclonal antisera, followed by horseradish peroxidase-conjugated antirabbit or anti-mouse immunoglobulin G (IgG), respectively, and visualized by chemiluminescence according to the manufacturer's instructions (Pierce Chemical Co., Rockford, IL, USA).
For immunoprecipitation, the cell lysates were incubated with the appropriate antibody for 1 h, followed by incubation with Gamma-bind beads (Amersham Biosciences, Piscataway, NJ, USA) for 1 h at 41C. Beads were washed four times with the buffer used for cell solubilization. Immune complexes were then eluted by boiling for 3 min in 2 Â Laemmli buffer, and extracts were analysed by immunoblotting as described above. GST pull-down assay was performed by incubating Glutathione-Sepharose 4B bead (Amersham Biosciences) with each extract for 1 h. After washing, the beads four times with the buffer used for cell solubilization, immunoblots were performed.
In vitro binding assay GST and GST-Smad3 fusion proteins were induced in DH5a or BL21 (DE3) with 0.1 mM isopropyl-1-thio-D-galactopyranoside for 3 h and subsequently purified by binding to Glutathione-Sepharose (Amersham Pharmacia Biotech Inc., Piscataway, NJ, USA). SRF protein was labeled with 35 Smethionine using the T7 quick-coupled transcription/translation system (Promega, Madison, WI, USA) The GST fusion proteins were incubated with SRF protein for 1 h at 41C in binding buffer (25 mM HEPES, pH 7.4, 150 mM NaCl, 1 mM MgCl 2 and 0.1% Triton X-100) containing protease and phosphatase inhibitors. After extensive washing in the same buffer, the bound SRF proteins were visualized by autoradiography.
Confocal microscopy
Mv1Lu cells stably expressing SRF were grown on 22-mm glass coverslips in a CO 2 -humidified incubator for 24 h. The cells were fixed in cold 3.5% paraformaldehyde for 5 min, permeabilized in cold absolute methanol for 2 min and then incubated for 5 min in 50 mM glycine to quench paraformaldehyde autofluorescence. The Smad3 and HA-tagged SRF proteins were detected by incubation at 41C with anti-Smad3 rabbit polyclonal (Zymed Laboratories Inc., South San Francisco, CA, USA) and anti-HA mouse polyclonal (F-7; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) antibodies, respectively. After being washed in phosphatebuffered saline (three times for 5 min each), the coverslips were incubated for 1 h at room temperature with fluorescein isothiocyanate-conjugated goat anti-rabbit IgG and tetramethyl rhodamine isocyanate-conjugated goat anti-mouse IgG secondary antibodies. The coverslips were then mounted in medium containing 4,6-diamino-2-phenylindole (DAPI) (Vector Laboratories, Burlingame, CA, USA). The cells were examined with a Leica TCS.NT laser scanning confocal microscope. A Â 63 oil-immersion objective was used. Appropriate emission filters, settings and controls were included to exclude bleed-through effects.
siRNA methods
We used the siRNA design tool (Dharmacon Inc., Lafayette, CO, USA) to identify target siRNAs. The SRF-specific sequence was 5 0 -UUCAGACCUGCCUCAACUC-3 0 (SRF nucleotides 1006-1024; GenBank Accession number BC052572). HeLa cells were seeded at 30% density the day before transfection. Transfections were performed by using TransIT-TKO reagent (Mirus, Madison, WI, USA) according to the manufacturer's instructions with 100 pmol of siRNA and 10 ml of transfection reagent/10 cm dish for HeLa cells.
Biotinylated DNA precipitation For binding of Smad3 to biotinylated DNA, HepG2 cells were transfected with Flag-tagged Smad3 and HA-tagged SRF. Cells were treated with 5 ng/ml TGF-b1 for 2 h. After preclearing with streptavidin-agarose for 1 h, cell lysates were incubated with 30 pmol of biotinylated double-stranded 3 Â CAGA oligonucleotides and 12 mg of poly(dI-dC) for 1 h. Proteins were precipitated with streptavidin-agarose for 30 min. After washing, DNA-bound proteins were subjected to SDS-PAGE, followed by Western blotting using antibodies.
Nothern blot analysis
Total RNA was prepared from Mv1Lu control and Mv1Lu-SRF cells using a TriZol kit (Invitrogen Corp., Rockville, MD, USA). Equal amounts of RNA were then separated in an agarose gel transferred onto a nylon membrane. Hybridization to 32 P-labeled DNA probes for PAI-1 and COL1A2 were carried out at 651C in Rapid-hybridization buffer (Amersham Biosciences). Hybridized bands were then visualized by autoradiography.
Measurement of DNA synthesis DNA synthesis rates were measured by the rate of [ 3 H]thymidine incorporation into DNA as described previously . Briefly, Mv1Lu vector control cells and Mv1Lu-SRF cells were plated in 24-well plates at a density of 5 Â 10 4 cells/well in 0.5 ml of growth medium. After treatment of cells with various doses of TGF-b for 20 h, cells were pulselabeled with 0.5 mCi of [ . A detailed protocol for chromatin crosslinking, immunoprecipitation and PCR was followed according to the manufacturer's instructions (Upstate USA Inc., Lake Placid, NY, USA).
Preparation of cytosolic and nuclear extracts SNU620-LXRN and SNU620-SRF stable cells were cultured on 100 mm dishes (70-80% confluence) and treated with TGFb1 (5 ng/ml) for 1 h. Cells were washed two times with ice-cold PBS and then collected by scraping in PBS, followed by brief centrifugation. Cell pellets were resuspended in 400 ml of icecold buffer A (10 mM HEPES, pH 7.5, 10 mM KCl, 0.1 mM EDTA, 1 mM dithiothreitol and protease inhibitors) and placed on ice for 30 min. After incubation, 25 ml of 10% NP-40 was added to the cell pellets, and tubes were vortexed vigorously for 10 s and centrifuged at 10 000 g for 30 s at 41C. The supernatants were saved as a cytoplasmic fraction. The nuclear pellets were briefly washed with buffer A and resuspended with 50 ml of buffer C (20 mM HEPES, pH 7.5, 0.4 M NaCl, 1 mM EDTA, 1 mM DTT and a tablet of protease inhibitor) followed by incubation for 15 min on the rocker at 41C. To collect the nuclear fraction, the tubes were centrifuged at 10 000 g for 15 min at 41C and then collected as nuclear extracts.
